Core Points - The company has established a system to enhance information disclosure, ensuring timely, accurate, and complete information is provided to investors [1] - The system outlines the responsibilities of reporting personnel in the event of significant events that could impact investor decisions or stock prices [1][2] - The board secretary is responsible for external information disclosure, including periodic and temporary reports [2][5] Group 1: Reporting Obligations - Reporting personnel include company directors, senior management, and other relevant individuals who may have access to significant information [1][2] - The first responsibility for internal information reporting lies with the general manager and other senior management [2][5] - Shareholders holding more than 5% of the company's shares must report relevant information to the board secretary and office [2][5] Group 2: Scope of Major Information - Major information includes significant events authorized by the board, major operational incidents, and changes in laws or regulations that could impact the company [3][4] - Related party transactions exceeding specified thresholds must be reported, including transactions with individuals over 300,000 yuan and with entities over 3 million yuan [3][4] - Legal matters involving amounts over 5 million yuan must also be reported, along with any significant discrepancies in performance forecasts [4] Group 3: Reporting Procedures - Reporting personnel must report significant information to the board secretary and office immediately upon becoming aware of it [5][6] - Reports can be made in various forms, including written documents, phone calls, or meetings [5][6] - The board secretary is responsible for analyzing reported information and proposing disclosure plans as necessary [6][7] Group 4: Responsibilities and Compliance - The board office assists the board secretary in managing information disclosure and responding to inquiries from the public and investors [7] - Failure to report significant information in a timely manner will result in accountability for the responsible personnel [7][8] - The board of directors is responsible for interpreting the system and ensuring compliance with relevant laws and regulations [8]

Core Viewpoint - The document outlines the compensation management system for the board of directors and senior management of Lushang Furuida Pharmaceutical Co., Ltd, aiming to enhance governance and establish effective incentive and restraint mechanisms [1] Group 1: General Principles - The compensation system is designed to motivate directors and senior management by linking their pay to the company's long-term interests, scale, performance, and individual contributions [3][4] - The system emphasizes a balance between incentives and constraints, ensuring that compensation reflects both company performance and individual responsibilities [3] Group 2: Management Structure - The Compensation and Assessment Committee of the board is responsible for evaluating directors and senior management, setting assessment standards, and determining compensation policies [2][3] Group 3: Compensation and Assessment Management - Independent directors receive a fixed monthly allowance approved by the shareholders' meeting, while non-independent directors receive compensation based on their roles without additional allowances [2][3] - Senior management's compensation consists of a fixed salary and performance-based pay, with the latter determined by annual operational goals and individual performance [2][3] Group 4: Compensation Adjustment - The compensation system is adaptable to align with the company's development strategy and can be adjusted in response to significant changes in the operating environment [6] - Special rewards or penalties can be established for specific matters, subject to approval by the Compensation and Assessment Committee and the board [6] Group 5: Implementation and Compliance - The compensation management system will be executed in accordance with national laws and regulations, and the board is responsible for its interpretation and revision [7]

Group 1 - The company aims to enhance its governance mechanism and strengthen internal control by establishing a system for independent directors to supervise information disclosure [1] - Independent directors are required to diligently fulfill their responsibilities during the preparation and disclosure of the annual report, ensuring the report is true, accurate, and complete [1][2] - The management must provide a comprehensive report on the company's operational status and significant matters to independent directors at the end of each fiscal year [2] Group 2 - Independent directors are responsible for verifying the qualifications of the accounting firm and the registered accountants involved in the annual audit [2] - The company’s financial officer must submit the annual audit plan and relevant materials to independent directors before the audit begins [2] - There should be necessary communication between independent directors and the registered accountants, including a meeting to discuss audit findings before the board meeting [2][3] Group 3 - The company’s secretary is responsible for facilitating communication between independent directors and the management team during the annual report preparation [3] - This working system will take effect after being approved by the company's board of directors [3] - Any matters not covered by this system will be executed according to national laws and regulations, and the company’s articles of association [3]

公司依据法律法规的要求应当报送的，需要将报送的外部单位相关人员作为内 幕知情人备案。公司应将报送的相关信息作为内幕信息，并书面提醒报送的外部单 位及相关人员履行保密义务，不得泄漏依据法律法规报送的本公司未公开重大信息， 不得利用所获取的未公开重大信息买卖本公司证券或建议他人买卖本公司证券。 第七条 公司依照统计、税收征管等法律法规的规定向政府有关部门或其他外部 单位报送公司尚未公开的重大信息（含经营财务数据等）的，或公司在进行申请授 信、贷款、融资、商务谈判等事项时因特殊情况确实需要向对方提供公司的尚未公 开重大信息的，需将报送的外部单位相关人员作为内幕信息知情人登记在案备查。 第八条 公司对外信息报送人员应当书面告知外部单位及其工作人员，因保密不 当致使前述重大信息被泄露时，应立即通知公司，公司应在知悉后的第一时间向上 海证券交易所报告并公告。 第一条 为加强公司定期报告及重大事项在编制、审议和披露期间的外部信息使 用人管理，依据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券 交易所股票上市规则》等法律、法规、规范性文件及《鲁商福瑞达医药股份有限公 司章程》（以下简称"公司章程"）等有关规定，制 ...

General Principles - The company aims to strengthen and standardize the management of asset impairment provisions to ensure financial statements accurately reflect its financial status and operational results [1] - Asset impairment refers to the situation where the recoverable amount of an asset is less than its book value, with recoverable amount defined as the higher of fair value less disposal costs and the present value of expected future cash flows [1][2] - The scope of asset impairment provisions includes financial assets, inventory, contract assets, long-term assets, and financial guarantee contracts [1][2] Asset Impairment Recognition Principles - If there are signs of asset impairment, a test must be conducted to assess potential impairment [2][3] - The company must identify signs of impairment based on actual conditions and conduct impairment tests on the balance sheet date if there is conclusive evidence [2][3] Financial Asset Impairment Provisions - The company conducts impairment tests on financial assets measured at amortized cost and those measured at fair value with changes recognized in other comprehensive income [3][4] - Impairment provisions are based on expected credit losses, which are calculated as the difference between all contractual cash flows and expected cash flows discounted at the original effective interest rate [3][4] Inventory Impairment Provisions - Inventory includes products held for sale, work in progress, and materials consumed in production [5] - A comprehensive inventory check must be conducted at the end of the period, and impairment provisions should be considered if market prices fall below book costs or if market prices are declining [5][6] Long-term Equity Investment Impairment Provisions - Long-term equity investments must be assessed for impairment on the balance sheet date based on specific indicators such as adverse changes in the political or legal environment affecting the investee [7] - Impairment provisions are recognized when the book value exceeds the recoverable amount, determined by the higher of fair value less costs to sell and the present value of expected future cash flows [7] Fixed Asset Impairment Provisions - Fixed assets must undergo impairment testing if they are idle, technologically obsolete, or damaged [8][9] - The recoverable amount is determined based on fair value less disposal costs and the present value of expected future cash flows [8][9] Investment Property Impairment Provisions - Investment properties measured using the cost model must recognize impairment if their recoverable amount falls below their book value due to market price declines or damage [9] Construction in Progress Impairment Provisions - Construction in progress must be analyzed for impairment, particularly if projects are halted for an extended period or if they are technologically outdated [10] Intangible Asset Impairment Provisions - Intangible assets must be tested for impairment if they are replaced by new technologies or if their market value significantly declines [11][12] Goodwill Impairment Provisions - Goodwill from business combinations must be tested annually for impairment, comparing the recoverable amount of related asset groups to their book value [12] Asset Impairment Provision Procedures - The finance department must regularly organize comprehensive checks of assets to identify potential impairment signs and prepare written reports detailing the basis, methods, amounts, and impacts of impairment provisions [13][14] Asset Loss Write-off Procedures - The company must confirm asset losses based on thorough verification and obtain legal evidence to support loss recognition [15][16] - The management of asset loss write-offs involves submitting reports and evidence for review, with specific thresholds for approval based on the amount of loss [15][16] Disclosure of Asset Impairment Provisions - The finance department is responsible for disclosing asset impairment provisions in financial reports, including significant impairment events and methods for determining impairment amounts [17] Implementation of the System - The asset impairment provision system is effective upon approval by the company's board of directors [18]

年报信息披露重大差错责任追究制度 第一章 总 则 第一条 为了提高公司的规范运作水平，确保信息披露的真实性、准确性、完整 性和及时性，提高年报信息披露的质量和透明度，根据《中华人民共和国公司法》、 《中华人民共和国证券法》 （以下简称"《证券法》"）、 《中华人民共和国会计法》 鲁商福瑞达医药股份有限公司 （以 下简称" 《会计法》"）、 《上市公司信息披露管理办法》 《上市公司治理准则》 《上海证 券交易所股票上市规则》等法律、法规、规范性文件及《鲁商福瑞达医药股份有限 公司章程》 （以下简称"公司章程"）的有关规定，结合公司实际情况，制定本制度。 第二条 本制度所指责任追究制度是指年报信息披露工作中有关人员不履行或 者不正确履行责任义务或其他个人原因，对公司造成重大经济损失或造成不良社会 影响时的追究与处理制度。 第三条 本制度适用于公司董事、高级管理人员、各子公司及子公司负责人、控 股股东及实际控制人以及与年报信息披露工作有关的其他人员。 第四条 实行责任追究制度，应遵循以下原则：实事求是、客观公正、有错必究； 过错与责任相适应；责任与权利对等原则。 《上海证券交易所股票上市规则》以 及中国证监会和上海 ...

第一条 为进一步强化鲁商福瑞达医药股份有限公司（以下简称"公司"）董事会审 计委员会监督职能，保障审计委员会委员切实履行勤勉尽责的义务，充分发挥审计委员会 在年报编制和披露方面的监督作用，根据中国证券监督管理委员会、上海证券交易所的有 关法律法规和《鲁商福瑞达医药股份有限公司章程》（以下简称"公司章程"）、《鲁商 福瑞达医药股份有限公司董事会专门委员会实施细则》及其他有关规定，制定本工作规程。 第二条 审计委员会在公司年度报告的编制和披露过程中，应当认真履行职责，勤勉 尽责。 第三条 在年度报告编制和审议期间，审计委员会委员负有保密义务。在年度报告披 露前，严防泄露内幕信息、内幕交易等违法违规行为发生。 第十二条 本工作规程由董事会负责制定并解释，并自董事会审议通过后实施，未尽 事宜依照有关法律、法规、规范性文件及公司章程的有关规定执行。 鲁商福瑞达医药股份有限公司董事会 第七条 审计委员会在年审外聘审计师进场后保持与外聘审计师的沟通，在外聘审计 师出具审计报告草稿后通过临时会议或传阅资料的方式再一次审阅公司财务会计报表，审 查外聘审计师是否独立客观及审计程序是否有效，形成书面意见。 第八条 公司年度财务会计 ...

第一章 总 则 第一条 为规范鲁商福瑞达医药股份有限公司（以下简称"上市公司"或"公 司"）募集资金的使用与管理，根据《中华人民共和国公司法》《中华人民共和 国证券法》《上市公司证券发行注册管理办法》《上市公司募集资金监管规则》 《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》，制定本规定。 第二条 本规定所称募集资金是指公司通过发行股票或者其他具有股权性质 的证券，向投资者募集并用于特定用途的资金，不包括公司为实施股权激励计划 募集的资金。 本规定所称超募资金是指实际募集资金净额超过计划募集资金金额的部分。 第三条 募集资金应严格限定用于公司在发行申请文件中承诺的募集资金投 资项目（以下简称"募投项目"）。公司变更募投项目必须在董事会审议后提交 股东会批准，并履行信息披露义务和其他相关法律义务。 第四条 公司董事会应当持续关注募集资金存放、管理和使用情况，有效防范 投资风险，提高募集资金使用效益。 公司的董事和高级管理人员应当勤勉尽责，确保公司募集资金安全，不得操 控公司擅自或者变相改变募集资金用途。 第二章 募集资金存储 （五）保荐人或者独立财务顾问可以随时到商业 ...

Core Viewpoint - The document outlines the management system for the shares held by directors and senior management of Lushang Furuida Pharmaceutical Co., Ltd, emphasizing compliance with relevant laws and regulations regarding shareholding and trading activities [1][12]. Group 1: General Provisions - The system is established to strengthen the management of shares held by directors and senior management in accordance with various laws and regulations [1]. - The system applies to directors, senior management, and other specified individuals or organizations regarding their shareholding and trading activities [1]. Group 2: Information Reporting - The company secretary is responsible for managing the data of directors and senior management regarding their shareholdings and must report any violations to regulatory authorities [2]. - Directors and senior management must report their personal information and any changes within two trading days [5]. Group 3: Share Locking and Unlocking - Shares held by directors and senior management will be locked upon reporting their personal information, and specific conditions apply for transferring shares [10][11]. - Upon leaving the company, directors and senior management's shares will be locked for six months, after which they will be automatically unlocked [15]. Group 4: Share Trading and Disclosure - Directors and senior management must notify the company secretary of their trading plans and adhere to regulations regarding insider trading [16][17]. - There are specific periods during which directors and senior management are prohibited from trading shares, including before financial report announcements [23]. Group 5: Share Transfer Limitations - There are restrictions on the transfer of shares by directors and senior management, including limits on the percentage of shares that can be transferred annually [19][20]. - The document specifies conditions under which shares cannot be transferred, such as during investigations or legal proceedings [18]. Group 6: Compliance and Enforcement - Violations of the regulations may result in penalties from regulatory authorities, and the company may impose its own sanctions based on the severity of the violation [29]. - The document grants the board of directors the authority to interpret the provisions and mandates compliance with relevant laws and regulations [30][31].

海证券交易所上市公司自律监管指引第 1 号——规范运作》等有关法律、法规、 规范性文件以及《鲁商福瑞达医药股份有限公司章程》的有关规定，结合公司实 际情况，制定本制度。 第二条 投资者关系管理是指公司通过便利股东权利行使、信息披露、互动 交流和诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资者对 公司的了解和认同，以提升上市公司治理水平和企业整体价值，实现尊重投资者、 回报投资者、保护投资者目的的相关活动。 第三条 投资者关系管理的基本原则 （一）合规性原则。公司投资者关系管理应当在依法履行信息披露义务的基 础上开展，符合法律、法规、规章及规范性文件、行业规范和自律规则、公司内 部规章制度，以及行业普遍遵守的道德规范和行为准则。 （二）平等性原则。公司开展投资者关系管理活动，应当平等对待所有投资 者，尤其为中小投资者参与活动创造机会、提供便利。 （三）主动性原则。公司应当主动开展投资者关系管理活动，听取投资者意 见建议，及时回应投资者诉求。 第一条 为规范鲁商福瑞达医药股份有限公司（以下简称"公司"）投资者 关系管理工作，加强公司与投资者之间的有效沟通，增强信息披露效能，促进投 资者对公司的了解和 ...